Scilex Dismisses Auditor BPM, Appoints Pipara & Co. Amid Going-Concern Doubts
SCLX sits 18% above its 52-week low of $0.543 on elevated volume (13× avg).
Summary
Scilex dismissed BPM LLP as its auditor and engaged Pipara & Co LLP for the September 30, 2026 quarter and fiscal 2026, disclosing no disagreements or reportable events. The change lands while the company carries a going-concern warning and minimal cash.
Key Events · Corporate Governance and Compliance · SCLX
-
Auditor Dismissed, Replacement Engaged
The audit committee approved dismissal of BPM LLP on November 11, 2026, with notice given November 16, 2026, and appointed Pipara & Co LLP on November 13, 2026 to audit the quarter and nine months ending September 30, 2026 and fiscal year 2026.
-
No Disagreements or Reportable Events
The filing states there were no disagreements with BPM on accounting principles, disclosure or audit scope, and no reportable events under Item 304(a)(1)(v) during the engagement period.
-
Prior Opinions Carried Going-Concern Language
BPM's reports for fiscal 2025 and 2024 were unqualified except for explanatory paragraphs citing substantial doubt about the company's ability to continue as a going concern.
-
New Auditor Already Audits Subsidiary
Pipara currently serves as independent auditor of Semnur Pharmaceuticals, a majority-owned Scilex subsidiary; its engagement was subject to customary client acceptance procedures.
Analysis · SCLX · Life Sciences
Weeks before it must report third-quarter results, Scilex swapped its independent auditor, replacing BPM LLP with Pipara & Co LLP — the same firm that already audits its majority-owned subsidiary Semnur. The filing states there were no disagreements and no reportable events, so this is not a restatement or a fight over accounting. But BPM's FY2025 and FY2024 opinions each carried a going-concern explanatory paragraph, and the company reported a $115.0 million Q2 2026 net loss with just $0.6 million of cash. A clean auditor change is routine; an auditor change at a company this close to the edge, with the new firm's first engagement covering the September 30, 2026 quarter, puts extra scrutiny on whether that 10-Q gets filed on time and without qualification. BPM has not yet delivered its required letter agreeing with the disclosure, so an amendment is still coming.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCLX was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.8M. The 52-week trading range was $0.54 to $16.81. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.